NCT06267001

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

A Phase III, Randomized, Double-blind Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 56 (actual)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study was to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered to participants with non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy.

Detailed description

With Protocol Amendment 2, enrollment will be stopped. The primary objective of the study has been changed to a safety objective and no other analysis will be conducted

Conditions

• Non-small Cell Lung Cancer (NSCLC)

Interventions

Type	Name	Description
DRUG	Atezolizumab	Atezolizumab will be administered IV.
DRUG	Tiragolumab	Tiragolumab will be administered IV.
DRUG	Placebo	Placebo will be administered IV.

Timeline

• Start date: 2024-03-21
• Primary completion: 2025-12-16
• Completion: 2025-12-16
• First posted: 2024-02-20
• Last updated: 2026-02-03

Locations

39 sites across 11 countries: Argentina, Australia, Brazil, China, Italy, Japan, Poland, South Korea, Taiwan, Thailand, Turkey (Türkiye)

Regulatory

• FDA-regulated drug study